Sanjivani Paranteral has announced that in order to strengthen the position of the company in solid dosages form in India and abroad, the company has acquired a new pharmaceutical manufacturing plant in Uttarakhand. The plant is WHO-GMP & MCA South Africa compliant and has capacity to produce 1000 million units of tablets and 10 million units of dry Syrups per annum. The company expects to add Rs 250 million per annum and Rs 50 million per annum to the top line and bottom-line respectively through this acquisition.
The company clocked an annual turnover of Rs 920 million for the year 2007-08 showing a growth of 32%. The acquisition of new plant and the growing export order book would see the annual turnover crossing the Rs 1250 million marks for the year 2008-09.
The company made this announcement during the trading hours today, 13 October 2008.
No comments:
Post a Comment